| Charles Austin Hunt Ii, MD | |
|
4721 Chace Cir, Hoover, AL 35244-3700 | |
| (205) 823-0151 | |
| (205) 823-5218 |
| Full Name | Charles Austin Hunt Ii |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 28 Years |
| Location | 4721 Chace Cir, Hoover, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699784538 | NPI | - | NPPES |
| 051120874 | Other | AL | BCBS |
| 51040048 | Other | AL | BCBS |
| H99246 | Other | AL | VIVA |
| 051120873 | Other | AL | BCBS |
| 051120872 | Other | AL | BCBS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brookwood Baptist Medical Center | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alabama Vein Specialists Group Llc | 9830410281 | 3 |
News Archive
Investigators from Dartmouth's Norris Cotton Cancer Center led by James Moseley, PhD have found that the protein Pom1 possesses the ability to modify different sets of proteins to coordinate the processes of cell growth and division.
So, you've genetically engineered a malaria-resistant mosquito, now what? How many mosquitos would you need to replace the disease-carrying wild type? What is the most effective distribution pattern? How could you stop a premature release of the engineered mosquitos?
The goal of this research was to create an ECM modified hyaluronic acid (HA) based hydrogel culture system that allows for the growth and differentiation of salivary acinar cells into functional acini-like structures capable of secreting large amounts of protein and fluid unidirectionally. Xerostomia, a condition resulting from irradiation of the head and neck, affects more than 40,000 cancer patients each year in the United States. According to this research, these patients will greatly benefit from the development of a functional implantable artificial salivary gland.
Advantech, a leading provider of industrial computing solutions, today announced a partnership with Imprivata, a digital identity solutions provider, for establishing interoperability with Imprivata OneSign, the leading healthcare enterprise single sign-on platform.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 8 days ago
| Entity Name | Alabama Vein Specialists Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972994473 PECOS PAC ID: 9830410281 Enrollment ID: O20151116001431 |
News Archive
Investigators from Dartmouth's Norris Cotton Cancer Center led by James Moseley, PhD have found that the protein Pom1 possesses the ability to modify different sets of proteins to coordinate the processes of cell growth and division.
So, you've genetically engineered a malaria-resistant mosquito, now what? How many mosquitos would you need to replace the disease-carrying wild type? What is the most effective distribution pattern? How could you stop a premature release of the engineered mosquitos?
The goal of this research was to create an ECM modified hyaluronic acid (HA) based hydrogel culture system that allows for the growth and differentiation of salivary acinar cells into functional acini-like structures capable of secreting large amounts of protein and fluid unidirectionally. Xerostomia, a condition resulting from irradiation of the head and neck, affects more than 40,000 cancer patients each year in the United States. According to this research, these patients will greatly benefit from the development of a functional implantable artificial salivary gland.
Advantech, a leading provider of industrial computing solutions, today announced a partnership with Imprivata, a digital identity solutions provider, for establishing interoperability with Imprivata OneSign, the leading healthcare enterprise single sign-on platform.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Austin Hunt Ii, MD 4721 Chace Cir, Hoover, AL 35244-3700 Ph: (205) 823-0151 | Charles Austin Hunt Ii, MD 4721 Chace Cir, Hoover, AL 35244-3700 Ph: (205) 823-0151 |
News Archive
Investigators from Dartmouth's Norris Cotton Cancer Center led by James Moseley, PhD have found that the protein Pom1 possesses the ability to modify different sets of proteins to coordinate the processes of cell growth and division.
So, you've genetically engineered a malaria-resistant mosquito, now what? How many mosquitos would you need to replace the disease-carrying wild type? What is the most effective distribution pattern? How could you stop a premature release of the engineered mosquitos?
The goal of this research was to create an ECM modified hyaluronic acid (HA) based hydrogel culture system that allows for the growth and differentiation of salivary acinar cells into functional acini-like structures capable of secreting large amounts of protein and fluid unidirectionally. Xerostomia, a condition resulting from irradiation of the head and neck, affects more than 40,000 cancer patients each year in the United States. According to this research, these patients will greatly benefit from the development of a functional implantable artificial salivary gland.
Advantech, a leading provider of industrial computing solutions, today announced a partnership with Imprivata, a digital identity solutions provider, for establishing interoperability with Imprivata OneSign, the leading healthcare enterprise single sign-on platform.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 8 days ago
Dr. Christopher Riddell Jones, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 5295 Preserve Pkwy, Ste 270, Hoover, AL 35244 Phone: 205-780-8980 Fax: 205-785-1554 |